FDA Chief Counsel Says Generic Firms Make Strong Case For Preemption
This article was originally published in The Pink Sheet Daily
Executive Summary
Generic product liability suits are on the rise, which could result in more generic drug makers arguing for federal preemption, Bradshaw says.